Add like
Add dislike
Add to saved papers

LncRNA NORAD contributes to colorectal cancer progression by inhibition of miR-202-5p.

Oncology Research 2018 Februrary 23
Previous study indicates that long noncoding RNA NORAD could serve as a competing endogenous RNA to pancreatic cancer metastasis. However, its role in colorectal cancer requires to be investigated. In the present study, we found that the expression of NORAD was significantly upregulated in colorectal cancer (CRC) tissues. Furthermore, the expression of NORAD was positively related with CRC metastasis and patients' poor prognosis. Knockdown of NORAD markedly inhibited CRC cell proliferation, migration and invasion but induced cell apoptosis in vitro. In vivo experiments also indicated an inhibitory effect of NORAD on tumor growth. In mechanism, we found that NORAD served as a competing endogenous RNA for miR-202-5p. We found that there was an inversely relationship between the expression of NORAD and miR-202-5p in CRC tissues. Moreover, overexpression of miR-202-5p in SW480 and HCT116 cells significantly inhibited cellular proliferation, migration and invasion. Taken together, our study demonstrated NORAD/miR-202-5p axis plays a pivot function on CRC progression.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app